Zhejiang Jingxin Pharmaceutical Re-Submits Hong Kong Listing Application with CITIC Securities as Sole Sponsor

Deep News
Sep 21

On September 18, Zhejiang Jingxin Pharmaceutical Co., Ltd. submitted a listing application to the Main Board of the Hong Kong Stock Exchange, with CITIC SEC acting as its sole sponsor.

This marks the company's second attempt at a Hong Kong IPO. Zhejiang Jingxin Pharmaceutical, which has been listed on the A-share market for over two decades, previously filed its initial application in February 2026, but the submission lapsed after the six-month validity period expired.

This content and data are compiled from public sources for reference only and do not constitute investment advice. Please verify before use.

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Most Discussed

  1. 1
     
     
     
     
  2. 2
     
     
     
     
  3. 3
     
     
     
     
  4. 4
     
     
     
     
  5. 5
     
     
     
     
  6. 6
     
     
     
     
  7. 7
     
     
     
     
  8. 8
     
     
     
     
  9. 9
     
     
     
     
  10. 10